Pharma companies continue to expand consumer segments with Sanofi-Aventis entering a vitamin and supplement joint venture in China and Novartis preparing to launch a nonprescription heartburn reliever in 14 European countries. Also, in the latest issue of "The Tan Sheet," we look at the impact of the centralized switch process in Europe on the OTC industry. Back in the States, we explore moves to make pseudoephedrine products Rx-only and a GAO investigation into new dietary ingredients.
[Editor's note: Keep up with this topic in 'The Tan Sheet,' your source for nonprescription pharmaceutical and nutritional industry news. For more information call 1-800-332-2181.Or you can request a free sample issue of 'The Tan Sheet' here.]
Sanofi Expands Consumer Health Reach With Minsheng VMS Joint Venture – Sanofi-Aventis enters a vitamin and supplement joint venture with China-based Minsheng Pharmaceutical. The deal further expands Sanofi's consumer health care empire and opens the door for Sanofi to distribute products in China
Novartis To Launch Nycomed's PPI Pantoloc Control in 14 European Countries – Under a co-marketing agreement with Nycomed, the Swiss firm looks to launch the proton pump inhibitor in 2010 Q2. The success of the pantoprazole heartburn relief aid hinges on whether Novartis' marketing can set it apart from other PPIs
European Switch Progresses, But Stronger Incentives Needed For OTCs – The OTC industry could "make commercial decisions" reducing its presence in Europe if the nonprescription regulatory climate does not grow more favorable, suggests GSK's Scheske at the Association of the European Self-Medication Industry Jan. 20 meeting in London. Experts discuss drawbacks to centralized switch and goals for smoother regulatory pathway.
Over-The-Counter
-
Novartis CEO Jimenez Highlights OTC Switches, Consumer Acquisitions
- C&D's First Response Line Extension Alerts Women One Day Earlier
- P&G Innovation Driving Market Share Gains Of Premium Products
On The Hill
- Wyden's Rx Pseudoephedrine Bill On Doorstep As States Continue Meth Fight
Regulatory
- OTC Dosing Device Guidance Elicits Concern On Spoon Confusion, Added Cost
- GAO New Dietary Ingredient Probe Has Puzzled Firms Seeking Legal Advice
Sales & Earnings
- Matrixx Initiatives Files Suite Against FDA On Unanswered FOIA Grounds
- J&J Expects Sales Loss To Be Skin-Deep, Looks To Skin-Care Lines For Boost
- Colgate's 2010 Product Pipeline Targets Niches In Oral Care, Deodorants
- Sales & Earnings In Brief
In Brief
- Sanofi-Aventis acquires marketing rights to Xyzal
- FDA warns Sunrise on Misbranded OTCs
- FDA says Cerebral Health makes unapproved claims
- NAD says hair supplement claims stretch accuracy
- NAD agrees with Prehistin supplement claims
- Pharmavite names Walsh COO
- Nordic Naturals donates, promotes for Haiti relief
- Science Board discusses CFSAN report
- MHRA switches domperidone maleate
-- Elizabeth Crawford
